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Abstract
Background: Aimed to assess the relationship between H.Pylori and the clinicopathological features and prognosis
of gastric cancer by quantitative detection of H.Pylori.
Methods: 157 patients were enrolled, all patients had a record of clinicopathological parameters. Specimens
including the tumor and non-neoplastic were detected for H.Pylori by Real-Time PCR and analyzed clinical data
retrospectively. Variables independently affecting prognosis were investigated by means of multivariate analysis
using the Cox proportional hazards model.
Results: H.Pylori infection was greater in non-neoplastic tissue than the tumor tissue (p < 0.05), H.Pylori infection
and its copies were related to the tumor site and N staging (p < 0.05). Overall survival (OS) in all 157 patients has
no correlation with the H.Pylori infection status (p = 0.715). As to the patients who underwent a curative surgery,
relapse-free survival (RFS) has no correlation with the H.Pylori infection status (p = 0.639). Among the H.Pylori
positive patients, OS and RFS of those with higher copies were longer than in patients with low copies, but there
was no significant statistical difference.
Conclusions: H.Pylori infection status and its copies were related to N staging. The OS and RFS in patients with
positive H.Pylori status has no significant difference from the patients with negative H.Pylori status.
Background
Gastric cancer is the second most common cause of
cancer death, though the incidence has decreased dra-
matically in some developed countries over the past dec-
ades [1], patients with this disease commonly have a
poor outlook[2]. Even after potentially curative surgery,
more than half the patients have tumor recurrence.
Lymph node involvement, depth of invasion, age, and
tumor location have been identified as the most signifi-
cant clinicopathologic prognostic factors[3,4]. However,
NCCN Clinical Practice Guideline of Gastric Cancer
suggests that patients with gastric cancer should eradi-
cate Helicobacter Pylori (H.Pylori) to reduce the risk of
recurrence, which was defined as class evidence[5].
H.Pylori, a Gram-negative microaerophilic spiral
bacterium, was first proposed to be associated with gas-
tric cancer by co-discoverer Marshall in 1983[6]. In
1994, the International Agency for Research on Cancer
(IARC) classified H.Pylori as a definite classI carcinogen
[7,8]. After that, a lot of studies have been carried out,
including epidemiological investigations[9], experimental
studies[10], animal experimental data[11,12], case con-
trol clinical trials[13,14]. Most of these studies strength-
ened the fact that H.Pylori is the main cause of gastric
adenocarcinoma. However, this point of view is still
controversial and more reliable data is required. How
H.Pylori infection leads to gastric cancer is not yet com-
pletely clear, as a variety of pathogenic factors may act
on different stages, such as virulence factors[15], DNA
damage, host factors[16,17] and COX-2[18]. The inci-
dence of gastric cancer is a multi-factor and multi-step
process.
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tionship between H.Pylori infection status or copies and
the clinicopathological features. Besides, the prognosis
differences in survival of patients who are positive for
H.Pylori compared with those who are negative remains
unknown. In a variable proportion of gastric cancer
patients, H.Pylori infection cannot be detected and dis-
tinct clinical and pathologic features have been
described in this subgroup [19,20]. Furthermore, a
recent German study provided evidence of a better
prognosis in patients with H.Pylori infection compared
with negative cases[21] and an Italian study showed that
negative H.Pylori status was associated with poor prog-
nosis in patients with gastric cancer [22]. However, to
our knowledge, these clinically relevant findings have
been not yet been validated in large experiences from
other centers. Most of these studies used serological
analysis as the only method to assess H.Pylori status, a
few of them even added the molecule method of PCR;
so the results of these studies are hardly convincing. In
fact, there are many types of methods provided for
detecting the H.Pylori, including culture, histopathologi-
cal diagnosis, urease test, molecule method, serological
analysis and UBT, but only culture, Real-Time PCR and
UBT have a high degree of sensitivity and specificity[23].
In the current study, we used the method of Real-
Time PCR to detect H.Pylori infection status and its
copies, and aimed to investigate the potential impact of
H.Pylori status on the clinicopathological features of
gastric cancer of patients who underwent surgery and
were followed up for a significant period of time to
assess differences in relapse-free survival and overall
survival.
Patients and Methods
Patients
The study population consisted of 157 consecutive
patients (107 men and 50 women) scheduled for surgery
from 1 January 2002 to 31 December 2006 at Sun Yat-
Sen University Cancer Center, GuangZhou, China. The
median age of the patients was 57.2 y (range: 27-78 y),
All patients enrolled in this study had a histologically
confirmed diagnosis of primary gastric cancer that was
confirmed pathologically after surgery. Patients who
underwent non-resective surgery, and those with Siewert
type I cardia adenocarcinoma were excluded from the
study, Patients with H.pylori eradication therapy or
treatment with antibiotics, bismuth-containing com-
pounds, H2-receptor blockers or proton pump inhibitors
within 4 weeks also had been excluded from the study.
Surgery consisted of subtotal or total gastrectomy in all
patients. A standardized technique was used for surgical
resection and lymphadenectomy, as described elsewhere
[3]. Age, sex, type of surgery, tumor location, TNM
stage, chemotherapy, specimen length, tumor size, and
tumor differentiation, were recorded for each patient in
a database. Tumor length and the width of fresh speci-
mens were recorded by the pathologists. pTNM classifi-
cation followed the criteria of the 6th edition of the
UICC[24]. All the patients who underwent any type of
chemotherapy were on the 5-FU-based regimen, and the
basic regimen was FOLFOX6 or XELOX. All Experi-
mental research that is reported in the manuscript have
obtained informed consent from the subjects of the
study and been Ethically performed with the approval of
an appropriate ethics committee in Sun Yat-sen Univer-
sity of Cancer Center.
Tumor tissue and non-neoplastic tissue from all
patients was collected from the resected specimen in the
operating room within 30 minutes after the removal of
the stomach. Non-neoplastic tissue was removed from
the normal gastric tissue at a distance of at least 5 cm
from the tumor. When neoplasm involved the entire
antrum, non-neoplastic mucosa was removed from the
middle or upper third of the stomach. Specimens were
immediately frozen in liquid nitrogen, processed, coded,
and stored at -80°C in a tissue bank located in the
laboratory of the scientific research department.
DNA Extraction and Real-Time PCR for H.Pylori
Both tumor tissue and Non-neoplastic tissue obtained
from all patients included in the study was retrieved
from the tissue bank. DNA was extracted from 50 mg
of solid tissue (both tumor and Non-neoplasitic) by
using the QIAamp DNA stool minikit (Qiagen). In
order to increase the yield of purified DNA, the whole
supernatant (500 μl) was used for further DNA purifica-
tion after the addition of the InhibitEX tablet, adapting
the following steps of the Qiagen protocol to this altered
sample amount. From H.Pylori isolates, DNA was
extracted by using the QIAamp DNA minikit according
to the protocol for isolation of genomic DNA from bac-
terial cultures (Qiagen).
GenBank was searched for sequences of the genes
encoding 16S rRNA of H.Pylori. The published
sequences were aligned by using CLUSTALW http://
www.ebi.ac.uk/clustalw/, and primers and probes were
designed by using Primer Express software (Perkin-
Elmer/Applied Biosystems, Foster City, Calif.) and the
LightCycler probe design software (Roche Diagnostics,
Mannheim, Germany). A BLAST search was performed
to check the specificity of the DNA sequences of the
primers and probes http://www.ncbi.nlm.nih.gov/
BLAST/.
The assay contained two PCR primers (DaAn Gene
Co., Ltd. of Sun Yat-sen University, GuangZhou, China):
primer1 F(5'- GCT AAG AGA TCA GCC TAT GTC
-3') and primer2 R(5'- CCG TGT CTC AGT TCC AGT
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16S rDNA, together with a probe, Tensensor (5'-
LCRed705-GCA TGT GGT TTA ATT CGA AGA TAC
ACphos- 3'), labelled with the fluorophore LC Red 705
(DaAn Gene Co., Ltd. of Sun Yat-sen University,
GuangZhou, China).
Each Real-Time PCR was performed in a final volume
of 50 μL containing a buffer of 10 μL(10 mM Tris-HCl
(PH8.0), 50 mM KCl and 1.5 mM MgCl2 ), 2 μLo f
cDNA, 1 μl of each primer(F 10 pmol/μl, R 10 pmol/μl),
1 μl of each deoxynucleotide(10 mM), 1 μl of Taq poly-
merase (3U/μl) (DaAn Gene Co., Ltd. of Sun Yat-sen
U n i v e r s i t y ,G u a n g Z h o u ,C h i n a )a n d1μl probe(DaAn
Gene Co., Ltd. of Sun Yat-sen University, GuangZhou,
China). Each reaction mixture was amplified as follows:
denaturation at 93°C for 3 minutes followed by 40 cycles
of denaturation at 93°C for 30 seconds; annealing at
55°C for 45 seconds; and extension at 72°C for 40 sec-
onds. Amplifications were performed with an ABI 7500
DNA engine (Applied Biosystems Inc, CA, USA). Used
H.Pylori standard amplification curves to make the stan-
dard curve linear regression graph, and then changed
the Ct values into the number of H.Pylori copies.
Follow up
All patients, after discharge from the hospital, entered a
follow-up program according to standard protocol[25].
Within the first 2 years after surgery, a follow-up every
3 months consisted of a clinical examination, routine
blood tests, assessment of concentration of tumor mar-
kers, and abdominal ultrasonography or CT scan; endo-
scopy was done every 6 months for the first 2 years
after surgery. For the next 3 years, patients were fol-
l o w e du pe v e r y6m o n t h sa n du n d e r w e n te n d o s c o p y
every 12 months. At relapse (defined as local recurrence
or metastasis at distant sites), all patients were staged
fully to detect disease at other sites. Survival was mea-
sured from the date of tumor resection to death or to
the last date the patient was known to be alive. The fol-
low-up was closed in December 2008. The mid follow-
up period was 24.4 months (range, 0.2-81.8 months).
Statistical Analysis
Cases were considered positive for H.Pylori when the
16S rRNA was present on Real-Time PCR product
amplification in either tumor tissue or the Non-neo-
plastic tissue, and the cases were defined as positive
for H.Pylori in normal tissue when the 16S rRNA was
present on Real-Time PCR product amplification in
Non-neoplastic tissue. All patients were divided into
two groups; Group A of 82 patients was comprised of
patients who were positive for H.Pylori infection,
Group B of 75 patients was comprised of patients who
had negative results for Real-Time PCR product
amplification. Furthermore, Group A was divided into
two groups by the median(1338.5copies) copies num-
ber of H.Pylori, one group of HP infection with high-
copies (≥1338.5 copy number) of 41 cases, the other
group of HP infection with low-copies (<1338.5 copy
number) of 41 cases.
Statistical analysis was performed by using SPSS soft-
ware for Windows (version 13.0; SPSS Inc, Chicago, IL).
The association between H-pylori infection status and
clinicopathological features was compared using Pearson
Chi-square test (2-tailed tests in each). The indepen-
dent-sample Student t test was used for comparison of
age at time of surgery. Relapse-free survival was calcu-
lated for all patients who had not had local or distant
relapse and overall survival was computed for those
patients who were alive, irrespective of relapse status.
Long-term survival was evaluated using the Kaplan-
Meier method, considering death or relapse from cancer
as the endpoint; patients who died of causes other than
tumor recurrence were considered as censored at the
time of death. The log-rank test was used for statistical
comparisons between factors. Variables independently
affecting prognosis were investigated by means of multi-
variate analysis using the Cox proportional hazards
model. The score statistic was used to select variables
for entry into the model. A statistical level of P < 0.05
was used for the inclusion of prognostic variables.
Results
H.Pylori Status as Determined by Real-Time PCR
Quantitative detection of H.Pylori from 157 cases of
patients with gastric cancer, each including tumor and
non-neoplastic tissue; a total of 314 specimens. 49
patients (31.2%) demonstrated positive H.Pylori in the
tumor tissue, and 69 patients (43.9%) demonstrated
p o s i t i v ei nt h en o n - n e o p l a s t i ct i s s u e( F i g u r e1 ) .T h e
combined positive in both tumor and non-neoplastic tis-
sue is 36 patients (22.9%), while 82(52.2%) patients can
be detected with H.Pylori in any one of the specimens.
Figure 1 Detection of H.Pylori in tumor and Non-neoplastic
tissue (two groups comparison P = 0.003).
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8.
The Association between Clinicopathologic Features and
H.Pylori Infection Status
Table 1 shows the results for a comparison of the clini-
cal and pathologic features between the patients in
G r o u pAa n dG r o u pB .O ft h ep a t i e n t si nG r o u pA ,
n e o p l a s m sw e r em o r ef r e q u e n t l yl o c a t e di nt h eu p p e r
stomach (37.8% vs 18%), and a more advanced pN clas-
sification(N2/N3) was observed while a more lower pN
classification(N0/N1) was seen in group B. Before sur-
gery, patients who were negative for H.Pylori had higher
concentrations of carcinoembryonic antigen(CEA) than
did those who were positive for H.Pylori. No statistical
significant differences with regard to gender, age, tumor
size, tumor site, gross type, depth of tumor invasion,
distant metastasis, UICC stage, CA199 and the P53 gene
expression were observed between the two groups.
The Association between Clinicopathologic Features and
H.Pylori Copies
The three clinicopathological features mentioned above
that were associated with the H.Pylori infection status
were analyzed to see whether they were associated with
the H.Pylori Copies. In Table 2, a comparison of the
clinical and pathologic features between the patients in
Group 1 with high-copies H.Pylori and Group 2 with
low-copies H.Pylori is reported.
Of the patients in the group with high-copies H.Pylori,
n e o p l a s m sw e r em o r ef r e q u e n t l yl o c a t e di nt h eu p p e r
stomach (51.2% vs 18%), and a more lower pN classifi-
cation(N0/N1) was observed while a more advanced pN
classification(N0/N1) was seen in the group with low-
copies H.Pylori. However, no statistical significant differ-
ence was observed in the concentrations of CEA
between the two groups (Table 2).
H.Pylori infection and Survival
The potential impact of H.Pylori status on the long-term
survival of patients was investigated by means of uni-
variate and multivariate analysis. Overall Survival analy-
sis was performed in 157 patients who underwent
surgery. At the end of follow-up, 75 patients were still
alive, 82 patients had died of tumor, and 1 patient had
died of other causes; the cancer-related 5-year survival
rate in the entire series was 48.4%.
Univariate analyses showed an association between
overall survival and histological differentiate, surgery,
UICC stage and concentration of CA-199(data not
shown). However, such association cannot be found
between H.Pylori infection status and overall survival
Table 1 Association Between Clinicopathologic Features
and H. Pylori Status
Clinicopathological
Features
Group A
(Positive)
(n = 82)(%)
Group B
(Negative)
(n = 75)(%)
P
value
Gender 0.287
Male 59(72.0) 48(64.0)
Female 23(38.0) 27(36.0)
Age 0.128
<57.2 years 45(54.9) 32(42.7)
≥57.2 years 37(45.1) 43(57.8)
Tumor site 0.040
Upper 31(37.8) 18(24.0)
Middle or Lower 51(62.2) 57(76.0)
Tumor size (Mean ± SD) 5.64 ± 2.82 5.84 ± 2.99 0.671
Gross type 0.816
Early GC I 1(1.2) 1(1.3)
Early GC III 10(12.2) 7(9.3)
Borrmann I 15(18.3) 12(16.0)
Borrmann II 37(45.1) 32(42.7)
Borrmann III 11(13.4) 15(20.0)
Borrmann IV 8(9.8) 8(10.7)
Histological Differentiate 0.236
Well 36(43.9) 28(37.3)
Poorly 35(42.7) 31(41.3)
Mucous/Signet-ring
cell
11(13.4) 16(21.3)
Depth of tumor invasion 0.749
T1 4(4.9) 2(2.7)
T2 9(11.0) 9(12.0)
T3 58(70.7) 54(72.0)
T4 11(13.4) 10(13.3)
Lymph-node metastasis 0.039
N0 30(36.6) 16(21.3)
N1 29(35.4) 29(38.7)
N2 14(17.1) 19(25.3)
N3 9(11.0) 11(14.7)
Distant metastases 0.822
M0 71(86.6) 64(84.0)
M1 11(13.4) 11(16.0)
UICC stage 0.124
I 10(12.2) 6(8.0)
II 20(24.4) 13(17.3)
III 32(39.0) 32(42.7)
IV 20(24.4) 24(32.0)
surgery 0.943
Curative 65(79.8) 62(85.3)
palliative 17(20.7) 11(14.7)
Tumor marker
CEA 0.026
<5 μg/L 64(11.0) 51(68.0)
≥5 μg/L 9 (78.0) 19(25.3)
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cal differentiate, surgery and UICC stage were indepen-
dent prognostic factors for overall survival.
Concentration of CA-199 was not significantly asso-
ciated with overall survival in multivariate analyses (data
not shown). The effect of H.Pylori status on prognosis
was observed in all the subgroups according to the
U I C Cs t a g ee x a m i n e d ;t h ed i f f e r e n c ew a sn o tf o u n dt o
be statistically significant (data not shown), In addition,
the effect of H.Pylori status on prognosis were evaluated
in all the subgroups regard to the different tumor sites,
the difference was not found to be statistically signifi-
cant (Additional files 1 and 2). Further analysis for the
patients who were positive for H.Pylori were performed;
Kaplan Meier survival analys i ss h o w e dt h a tt h eo v e r a l l
survival in patients with high copies H.Pylori infection
was better than in the patients with low copies, but the
difference was not statistically significant (P = 0. 068)
(Figure 3.) The association between H.Pylori copies and
prognosis were evaluated in all the subgroups regard to
the different tumor sites, There is no statistically signifi-
cance (Additional files 3 and 4).
Relapse-Free Survival analysis was performed in 129
patients who underwent R0 resection. At the end of fol-
low-up, 73 patients were still alive, 56 patients had died
of tumor recurrence or distant metastasis. The potential
impact of H.Pylori status on the relapse-free survival of
patients was investigated by means of univariate and
multivariate analysis.
Univariate analyses showed an association between
relapse-free survival and histological differentiate, tumor
site, depth of tumor invasion (pT stage), Lymph-node
metastasis (pN stage). However, such association cannot
be found between H.Pylori infection status (p = 0.639)
(Figure 4), the number of H.Pylori copies, H.Pylori
infection in the non-neoplastic tissue and relapse-free
survival. In multivariate analyses, histological differenti-
ate, tumor site, depth of tumor invasion (pT stage),
Table 2 The Association between Clinicopathologic
Features and H.Pylori Copies
H.Pylori
high-titer
(41cases, %)
H.Pylori
low-titer
(41cases, %)
P value
Tumor site 0.013
Upper 21(51.2) 10(24.4)
Middle or Lower 20(48.8) 31(75.6)
Lymph-node metastasis 0.014
N0 20(48.8) 10(24.4)
N1 13(31.7) 16(39.0)
N2 6(14.6) 8(19.5)
N3 2(4.9) 7(17.1)
CEA 0.269
<5 μg/L 34(82.9) 30(73.2)
≥ 5 μg/L 3(7.3) 6(14.6)
Table 1 Association Between Clinicopathologic Features
and H. Pylori Status (Continued)
CA199 0.346
<30 μg/L 44(53.7) 44(58.7)
≥30 μg/L 12(14.6) 18(24.0)
P53 0.827
positive 9(11.0) 8(10.7)
negative 40(48.8) 40(53.3)
Figure 2 Association between overall survival and H. Pylori
infection Status of 157 patients with gastric cancer (p = 0.715).
Figure 3 Association between overall survival and the number
of H.Pylori copies in patients who were positive for H.Pylori
(P = 0. 068).
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prognostic factors for relapse-free survival. The effect of
H.Pylori status on prognosis was observed in all the sub-
groups according to the UICC stage examined, the dif-
ference was not found to be statistically significant (data
not shown). Data for overall survival of the patients who
underwent R0 resection were almost the same as those
for relapse-free survival. Histological differentiate, tumor
site, depth of tumor invasion (pT stage), Lymph-node
metastasis (pN stage) were independent prognostic fac-
tors for overall survival (data not shown).
Discussion
Among the numerous methods described above, the
most promising for the future is the application of Real-
Time PCR [26]. The new real-time PCR technique is a
breakthrough in the diagnosis of H.Pylori because it
allows not only a quick and precise detection of H.Pylori
but also its quantification [23]. In the method of Real-
Time PCR, there are many genes to select for amplifica-
tion, and the primer pair 16S rRNA and 23S rRNA
showed a high specificity and sensitivity [27]. In the cur-
rent study, we chose the 16S rRNA for amplification of
Real-Time PCR; the results showed that 52.2% of 157
gastric cancer were positive for H.Pylori infection, which
approached the results of other studies using the same
method[28].
The main findings of the current study were: 1) H.
Pylori infection was greater in non-neoplastic tissue
than in tumor tissue; 2) H.Pylori infection was related to
the tumor site, N staging, as well as the level of CEA;
moreover, tumor site and N staging was related to the
H.Pylori copies number. In Highly-infected patients, the
N staging had an earlier stage(N0/N1) and tumor sites
in upper stomach were found, while the CEA level was
unrelated to the H.Pylori copies number; and 3) the
overall survival and relapse-free survival in patients with
positive H.Pylori status had no significant difference
from the patients with negative H.Pylori status; and in
H.Pylori positive patients, prognosis was better in those
with high copies number of H.Pylori than in those with
lower copies number, but the result was no significant
statistical difference.
We recorded a higher frequency of infection with H.
Pylori in non-neoplastic tissue than in the tumor tissue
of the patients with gastric cancer. The possible expla-
nation could be that 1) once a tumor arose in the loca-
tion where the H.Pylori lived, the tumor would change
the microenvironment, which would not be suitable for
t h eH . P y l o r it os u r v i v ei na n ym o r e . 2 )S o m es c h o l a r s
[29]pointed out that the H.Pylori would be engulfed by
the neutrophilic granulocyte, which is abundant in the
neoplastic tissue. The host immune response to the
tumor increases the induction of apoptosis by the
bacteria.
The clinicopathological features of H.Pylori-positive
patients were compared with those of the group of
patients with negative H.Pylori status. Statistical analysis
revealed that upper stomach location was more frequent
in H.Pylori-positive patients; among the patients who
were positive for H.Pylori, the copies of H.Pylori in
upper stomach location were also higher than in the
middle or lower stomach. In general, the stomach, espe-
cially the gastric pylorus is the most suitable place for
H.Pylori to grow. Diagnosis and quantity of H.pylori
infection was performed using non-neoplastic tissue at a
distance of at least 5 cm from tumor. Therefore, sam-
pling sites were different according to tumor site, for
example, the upper stomach cancer may sample non-
neoplastic tissue from the middle or lower stomach, and
the middle or lower stomach cancer may sample from
the upper. Furthermore, One point sampling from
antrum or corpus may result in sampling error of H.
pylori diagnosis and assessment of H.pylori amount, so
we think this result is not able to conclude that H.Pylori
infection was related to the tumor site.
We also found a higher rate of more advanced pN
stage in H.Pylori-negative patients; furthermore, pN sta-
ging was related to the H.Pylori copies number. In the
high-copies patients, the N staging has an earlier stage
(N0/N1). Theoretically, tumor invasion and metastasis
associated with the matrix metalloproteinases (MMPs)
secreted by the gastric cancer cell, which can degrade
extracellular matrix, change the structure of vascular
basement membrane and promote cancer cell invasion
and metastasis[30,31]. MMP-2 is one of the most
important MMPs in the process of tumor invasion and
Figure 4 Association between relapse-free survival and
H. Pylori infection of 129 patients who underwent curative
surgery (p = 0.639).
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expression has a strong correlation with progress of
lymph node metastasis of gastric cancer. Once H.Pylori
has infected the stomach, it can stimulate the secretion
of MMP-1, MMP-2, MMP-3 and TIMP-3 from gastric
cancer cell[33], and finally prompt and speed up the
progress invasion and metastasis of gastric cancer. How-
ever, the current study showed a converse conclusion,
so we suggest that the H.Pylori infection is a beneficial
factor for lymph-node metastasis.
Data from the current study indicated that H.Pylori
infection was related to the level of CEA in the host
serum. To our knowledge, it is the first time to report
such an influence of this factor on the level of CEA.
Patients with positive H.Pylori status had a low level
compared with those who were negative, but the level of
CEA was unrelated to the H.Pylori copies number; a
possible explanation was autoimmune responses induced
by H.Pylori inhibited the growth of cancer cell[34], and
finally decreased the level of CEA in the host serum.
Dating back to 1995, studies from Taiwan[35,36], to
our knowledge, was the first to report the relationship
between H.Pylori infection status and the outcome of
the patients with gastric cancer, multivariate analysis
demonstrated that only TNM stage was the independent
prognostic factor; however, the definition of H.Pylori
status was performed only by serology, the number of
patients was small, and follow-up was rather short. In
2006, a prospective study identified H.Pylori status as an
independent prognostic factor [21]. Culture examina-
tion, histologic analysis, and serologic assay were per-
formed to define H.Pylori status. The better prognosis
noted in patients with H.Pylori infection was explained
on the basis of an improved immune response against
the tumor [21]. It also has been assumed that because
H.Pylori components mimic specific receptors or surface
molecules on gastric epithelial cells, auto-antibodies
could induce a cross-reaction against gastric cancer cells
[34]. However, several authors have raised doubts
regarding the real prognostic value of H.Pylori status,
suggesting that H.Pylori negativity may be simply related
to more advanced tumor progression [37,38]. A recent
study in Italy[22] revealed that patients with negative H.
Pylori status appeared to have a poor prognosis, but the
methods of this study is also doubtful, since they used
the combination methods PCR for vacA and Serologic
analysis to define the status of H.Pylori infection. Theo-
retically, PCR can detect only one copy of the target
DNA when tested in water, but most studies have
shown that standard PCR sensitivity and efficacy were
not so exact [23,39], and the serologic analysis cannot
distinguish whether the patient is having a current infec-
tion or an infection of the past[23,40]; both of the meth-
ods will contribute in part to a false negative.
We have shown that the UICC stage, histological dif-
ferentiate and surgery were the independent prognostic
factors of the overall survival of all the patients with
gastric cancer, and the tumor site, histological differenti-
ate, depth of tumor invasion, lymph-node metastasis
were the independent prognostic factors of the relapse-
free survival for the patients who underwent curative
surgery. However, the H.Pylori infection status was not
an independent prognostic factor as there was no differ-
ence in the survival of these patients with or without H.
Pylori, but further analysis of H.Pylori positive patients
revealed that the prognosis of those with high copies
number of H.Pylori was better than those with low
copies number, but the result was no significant statisti-
cal difference.
In vaccination experiments[41] with cholera toxoid in
human beings, H.Pylori infection acts as an adjuvant for
the induction of a local B-cell response in gastric
mucosa. Furthermore, presentation of tumor antigens in
the setting of inflammation might induce stronger
immune responses in the presence of H.Pylori, and the
cellular immune response caused by H.Pylori displays a
type-1 T-helper-cell (Th1) type[42]. Thus, if the relation
between a type 1 response and antitumor activity is con-
firmed by further studies, H.Pylori might contribute to
an improved immune response against the tumor. How-
ever, some scholars cast doubt on this hypothesis;
whether the patients who were negative for H.Pylori
infection obtain a better outcome or not demands more
evidence [37]. In fact, the results of the current study do
not confirm this hypothesis; we suggest that the H.Pylori
infection in patients with gastric cancer can induce the
host’s immune responses to the tumor, and finally have
an effect on the lymph-node metastasis, but the immune
responses were not so strong as to show an advantage in
the survival eventually.
A trend toward a higher survival rate was observed in
patients with high-copies H.Pylori infection compared
with patients with low-copies infection, but the differ-
ence was not found to be statistically significant. This
trend may be because of a higher protective effect of
actual infection on long-term survival. Potential associa-
tions between the copies of H.Pylori infection and long-
term survival should be investigated in further studies to
clarify whether high-copies H.Pylori infection could be
associated with a better prognosis in patients with gas-
tric cancer.
Another question of whether patients with H.Pylori
infection should undergo eradication after surgery
remains unresolved. A study from Uemura et al.[43]
conducted a nonrandomized H.Pylori eradication trial in
patients whose gastric cancer was removed by endo-
scopic resection after the long-term clinical and endo-
scopic follow-up. The final result found that H.Pylori
Qiu et al. BMC Cancer 2010, 10:374
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Page 7 of 9eradication may improve neutrophil infiltration and
intestinal metaplasia in the gastric mucosa and inhibit
the development of new carcinomas. This study was
based on patients with early gastric carcinoma, but
whether these results were suited for advanced gastric
cancer remains unclear. However, the results of the cur-
rent study show that there is no difference of relapse-
free survival in patients with or without H.Pylori infec-
tion in the non-neoplastic tissue.
Conclusions
H.Pylori continues to be one of the most common bac-
terial infections in human. Although enormous progress
has been made in studying the virulence factors of H.
Pylori and their variation, this information has not yet
been used in clinical practice. Associations between bac-
terial characteristics and disease risks have not yet been
defined sufficiently well to guide the clinician in treat-
ment decisions.
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